康辰药业：KC1086项目获临床试验通知书

Core Viewpoint - Kangchen Pharmaceutical (603590) has received approval from the National Medical Products Administration for the clinical trial of its innovative chemical drug KC1086, which is a small molecule inhibitor targeting KAT6 for the treatment of advanced recurrent or metastatic solid tumors [1] Group 1: Drug Development - KC1086 is a novel, highly selective small molecule inhibitor of lysine acetyltransferase 6 (KAT6) [1] - KAT6 is abnormally expressed in various tumor types, and inhibiting KAT6 can effectively suppress tumor cell growth and has potential clinical applications in reversing tumor resistance and treatment [1] Group 2: Efficacy and Research Findings - KC1086 has demonstrated excellent in vivo efficacy in various mouse transplantation tumor CDX/PDX models [1] - In the ER+/HER2- breast cancer efficacy model, KC1086 showed a tumor suppression rate exceeding 90%, with similar effects observed in other solid tumor efficacy models [1]